LLY Stock Intrinsic Value – ELI LILLY: Leading Growth Stock with Strong EPS Projections in the Pharmaceutical Industry

☀️Trending News

ELI ($NYSE:LLY) LILLY is a leading pharmaceutical company known for its innovative medicines and commitment to improving global health. The company’s stock has consistently outperformed the broader market, making it a favorite among both individual and institutional investors. One of the key factors driving ELI LILLY‘s growth is its strong earnings per share (EPS) projections. EPS is a measure of a company’s profitability and is calculated by dividing its net income by the number of outstanding shares. ELI LILLY has consistently delivered strong EPS numbers, with projections showing further growth in the coming years. The company’s focus on developing new and innovative medicines has been a major contributor to its strong EPS projections. In addition to its impressive pipeline of new drugs, ELI LILLY also has a strong portfolio of established products.

These include well-known medications such as Humalog, Cialis, and Prozac, which continue to generate significant revenue for the company. This allows ELI LILLY to tap into new markets and reach a wider patient population, further driving its growth potential. Moreover, ELI LILLY has a strong financial position, with a solid balance sheet and healthy cash flows. This provides the company with the resources to continue investing in its research and development efforts, as well as pursue strategic acquisitions and partnerships to further expand its portfolio. With a commitment to improving global health and a track record of delivering strong returns for investors, ELI LILLY is a company that continues to stand out in the competitive healthcare sector.

Earnings

In its earning report for the fourth quarter of fiscal year 2023, which ended on December 31, 2021, the company reported a total revenue of 8.0 billion USD and a net income of 1.73 billion USD. While this marks a 9.6% increase in total revenue compared to the previous year, there was a slight decrease of 10.8% in net income. Despite the decrease in net income, ELI LILLY‘s overall financial performance remains impressive, with a steady growth in total revenue over the past three years. In fact, the company’s total revenue has grown from 8.0 billion USD to 9.35 billion USD in just three years, indicating a positive trajectory for the company’s future. ELI LILLY’s success can be attributed to its strong presence in the pharmaceutical industry, with a diverse portfolio of medications and treatments for various ailments.

The company has also been investing in research and development, constantly striving to innovate and introduce new and improved treatments. Furthermore, ELI LILLY has established itself as a leader in the market by consistently meeting or exceeding earnings expectations and delivering strong financial results. This has resulted in a loyal investor base and has positioned the company as a top growth stock in the industry. With a solid track record of financial performance and a promising future outlook, the company continues to be a top choice for investors looking for a stable and growing stock in the competitive healthcare sector.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for LLY. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for LLY. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for LLY. More…

Key Ratios Snapshot

Some of the financial key ratios for LLY are shown below. More…

Market Price

On Friday, the company’s stock opened at $899.73 and closed at $892.7, showing a slight increase of 0.15% from the previous closing price of 891.32. This upward trend in ELI LILLY AND’s stock price can be attributed to its solid financial performance and promising future prospects. The company has consistently reported strong earnings per share (EPS) growth, indicating its ability to generate profits for its shareholders. In fact, analysts have projected a further increase in EPS for the company in the coming years. One of the key factors contributing to ELI LILLY AND’s success is its robust pipeline of new drugs and treatments. The company invests heavily in research and development to bring innovative and effective medicines to the market. This has not only helped the company in expanding its product portfolio but also in securing a strong competitive position in the industry. Moreover, ELI LILLY AND has been actively pursuing strategic partnerships and acquisitions to expand its reach and diversify its offerings. This move is expected to drive growth for the company in the long run.

Additionally, ELI LILLY AND’s focus on global expansion has proven to be fruitful. The company has a strong presence in emerging markets like China and India, where the demand for pharmaceuticals is continuously growing. Its international sales have been steadily increasing, contributing significantly to its overall revenue growth. With a solid pipeline of new products and strategic initiatives in place, the company is well-positioned for continued success and growth in the future. Live Quote…

Analysis – LLY Stock Intrinsic Value

As a financial analysis company, GoodWhale has conducted a thorough examination of the financials of ELI LILLY AND. Our analysis has revealed some key points that investors should consider when looking at this company. Firstly, we have calculated the intrinsic value of ELI LILLY AND’s shares to be around $414.8. This value has been determined by our proprietary Valuation Line, which takes into account various financial metrics such as earnings, cash flows, and growth prospects. This suggests that the stock is currently overvalued by 115.2%, as it is currently trading at $892.7. This overvaluation may be a cause for concern for investors, as it indicates that the stock may not have much room for further growth and may even be at risk of a potential correction. It is important to note that this overvaluation is based on our calculations and may not necessarily reflect the market sentiment. Additionally, our analysis has also considered other important factors such as ELI LILLY AND’s financial health and performance. We have found that the company has a solid financial standing, with steady revenue and profit growth over the past few years. However, there are also some concerns about its high levels of debt. In conclusion, while ELI LILLY AND may be a strong and reliable company, investors should carefully consider its current overvaluation and make informed decisions about their investments. As always, it is important to conduct thorough research and consult with a financial advisor before making any investment decisions. More…

Peers

The competition between Eli Lilly and Co and its competitors is intense. Biogen Inc, Pfizer Inc, and Merck & Co Inc are all major players in the pharmaceutical industry, and each company is striving to be the top dog. Eli Lilly and Co has a strong presence in the United States, but its competitors are not far behind.

– Biogen Inc ($NASDAQ:BIIB)

Biogen Inc is an American multinational biotechnology company. The company is headquartered in Cambridge, Massachusetts, and has offices in Weston, Massachusetts; Research Triangle Park, North Carolina; Zurich, Switzerland; Maidenhead, United Kingdom; and Tokyo, Japan. Biogen Inc researches, develops, and manufactures therapies for the treatment of neurological and neurodegenerative diseases. The company’s products include AVONEX, TYSABRI, and FAMPYRA.

– Pfizer Inc ($NYSE:PFE)

Pfizer Inc has a market cap of 244.98B as of 2022, a Return on Equity of 24.63%. The company focuses on the discovery, development, and manufacture of biopharmaceutical products. Its portfolio includes medicines and vaccines for a wide range of conditions and diseases, such as Alzheimer’s disease, arthritis, cancer, and diabetes.

– Merck & Co Inc ($NYSE:MRK)

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. The company was established in 1891 as the United States subsidiary of the German company Merck, which was founded in 1668 by the Merck family. Merck & Co. was subsequently acquired by Schering-Plough in 2009, and then by Merck KGaA in 2014. The company is headquartered in Kenilworth, New Jersey, and employs approximately 70,000 people in more than 140 countries.

Merck’s market cap is 238.43B as of 2022. The company has a Return on Equity of 28.84%. Merck & Co. is a multinational pharmaceutical company that is one of the largest in the world. The company was established in 1891 and has been acquired by Schering-Plough in 2009, and then by Merck KGaA in 2014. Merck & Co. is headquartered in Kenilworth, New Jersey, and employs approximately 70,000 people in more than 140 countries.

Summary

Eli Lilly is a top growth stock with promising EPS projections. The company has consistently shown strong financial performance, with its latest earnings report beating analyst expectations. This can be attributed to a growing demand for its pharmaceutical products, particularly in the areas of diabetes and cancer treatment.

Additionally, Eli Lilly has a robust pipeline of potential new drugs, providing potential for future growth. The company also has a solid balance sheet and a history of increasing dividends, making it an attractive option for investors looking for both growth and income.